IL13Rα2-BBz-GLUT1 CAR-T cells

IL13Rα2-BBz-GLUT1 CAR-T cells are an experimental **autologous engineered CAR-T cell therapy** designed for solid tumors, particularly **glioblastoma**. The construct uses an **IL13Rα2-directed chimeric antigen receptor** with **4-1BB and CD3ζ signaling domains** and adds **enforced GLUT1 overexpression** to improve glucose uptake and metabolic fitness in the nutrient-poor tumor microenvironment. In preclinical orthotopic glioblastoma models, these cells showed improved antitumor activity, reduced exhaustion-associated phenotypes, and prolonged survival versus comparator IL13Rα2-BBz CAR-T cells without GLUT1 augmentation. Based on the provided evidence, this appears to be a **preclinical academic-stage cell therapy construct** rather than a branded or company-identified commercial product.

Other names

IL13Ra2-BBz-GLUT1 CAR-T cellsIL-13Ra2-BBz-GLUT1 CAR-T cellsIL 13Ra2-BBz-GLUT1 CAR-T cellsIL13Rα2-BBz CAR-T cells overexpressing GLUT1GLUT1-overexpressing IL13Rα2-BBz CAR-T cells